Risperidone versus haloperidol in children and adolescents with AD

Miral, Süha; Gencer, Özlem; Inal-Emiroglu, F. Neslihan; Baykara, Burak; Baykara, A; Dırık, Eray

doi:10.1007/s00787-007-0620-5

Cited by 102 publications

(44 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Risperidone was also found to be superior to haloperidol in a head-tohead trial using ABC-Total. 45 On the Childhood Psychiatric Rating Scale, clomipramine, 46 naltrexone, 47 and a vitamin and mineral supplement (containing 19 vitamins and 9 minerals) 48 revealed improvement as compared with placebo. Highdose pyridoxine and magnesium (HDPM) 49 and tetrahydrobiopterin 50 were not statistically distinguishable from placebo.…”

Section: Effi Cacymentioning

confidence: 98%

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

et al. 2016

View full text Add to dashboard Cite

BACKGROUND: Autism spectrum disorder (ASD) is increasingly recognized as a public health issue. Irritability and aggression (IA) often negatively affect the lives of people with ASD and their families. Although many medications have been tested for IA in ASDs in randomized controlled trials (RCTs), critical quantitative analyses of these trials are lacking in the literature. OBJECTIVES:To systematically review and quantitatively analyze the efficacy and safety of pharmacologic treatments for IA in youth with ASD.DATA SOURCES: Studies were identified from Medline, PsycINFO, Embase, and review articles. METHODS:Original articles on placebo-controlled RCTs of pharmacologic treatments of IA in youth age 2 to 17 years with ASD were included. Data items included study design, study goals, details of study participants, details of intervention, study results, statistical methods, side effects, and risks of bias. The primary study outcome measure was the effect size of reduction in the Aberrant Behavioral Checklist-Irritability (ABC-I) scores in the medication group, as compared with placebo, in RCTs using parallel groups design. RESULTS:Forty-six RCTs were identified. Compared with placebo, 3 compounds resulted in significant improvement in ABC-I at the end of treatment. Risperidone and aripiprazole were found to be the most effective, with the largest effect sizes. Sedation, extrapyramidal sides effects, and weight gain were assessed quantitatively. CONCLUSIONS:Although risperidone and aripiprazole have the strongest evidence in reducing ABC-I in youth with ASD, a few other compounds also showed significant efficacy with fewer potential side effects and adverse reactions in single studies.

show abstract

Section: Effi Cacymentioning

confidence: 98%

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These strong studies suggest there may be a role for haloperidol in cases of severe, refractory negative behaviors. Miral et al (2008) compared haloperidol to risperidone in a head-to-head investigation. This study obtained only adequate research strength due, in part, to use of a non-systematic diagnostic system for ASD.…”

Section: Haloperidolmentioning

confidence: 99%

Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice

Siegel

Beaulieu

2011

J Autism Dev Disord

129

View full text Add to dashboard Cite

This paper presents a systematic review, rating and synthesis of the empirical evidence for the use of psychotropic medications in children with autism spectrum disorders (ASD). Thirty-three randomized controlled trials (RCTs) published in peer-reviewed journals qualified for inclusion and were coded and analyzed using a systematic evaluative method specific to autism research (Reichow et al. in Journal of Autism and Developmental Disorders 38:1311-1319, 2008). Results are presented by agent and primary target symptom(s). The findings suggest established evidence for relatively few agents, with preliminary and promising evidence for a larger group. Challenges and opportunities in the developing field of ASD psychopharmacology are identified, and recommendations for further research are provided.

show abstract

“…There are no described molecular mechanisms that are affected by (n − 3) fatty acids in autism, and the evidence that any nutritional or pharmacological component can produce any improvement is derived from a group of pilot studies (Chez et al, 2007;Dosman et al, 2007;Miral et al, 2008). One preliminary study found that average total levels of omega-3 (n−3 PUFAs) in the autistic children were about 20% lower than mentally retarded children used as controls.…”

Section: Discussionmentioning

confidence: 99%

A possible association between elevated serum levels of brain-specific auto-antibodies and reduced plasma levels of docosahexaenoic acid in autistic children

Mostafa

El-Khashab

Al-Ayadhi

2015

Journal of Neuroimmunology

View full text Add to dashboard Cite

Risperidone versus haloperidol in children and adolescents with AD

Abstract: Risperidone was found to be more effective than haloperidol in the treatment of behavioral symptoms, impulsivity, language skills, and impaired social relations in children with AD. These results demonstrated that both drugs were safe and well tolerated in the treatment of AD.

Cited by 102 publications

References 31 publications

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

Pharmacologic Treatment of Severe Irritability and Problem Behaviors in Autism: A Systematic Review and Meta-analysis

Psychotropic Medications in Children with Autism Spectrum Disorders: A Systematic Review and Synthesis for Evidence-Based Practice

A possible association between elevated serum levels of brain-specific auto-antibodies and reduced plasma levels of docosahexaenoic acid in autistic children

Contact Info

Product

Resources

About